Lenalidomide - Latest Advances

Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.

Journal: Expert opinion on biological therapy

Published: December 12, 2025

Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review.

Journal: Acta clinica Belgica

Published: December 12, 2025

Vitamin D status and chemotherapy-induced peripheral neuropathy: A scoping review.

Journal: Nutrition and health

Published: December 08, 2025

Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Updates in low/intermediate-risk MDS.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Choosing the optimal maintenance strategy in multiple myeloma.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Collapsing Glomerulopathy in a Patient With Myelodysplastic Syndrome With Isolated del(5q): A Case Report.

Journal: Kidney medicine

Published: December 01, 2025

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan.

Journal: Current medical research and opinion

Published: November 26, 2025

NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.

Journal: Leukemia & lymphoma

Published: November 19, 2025

Daratumumab-Based Regimen Significantly Induced Remission of Crystalline Light Chain Proximal Tubulopathy: A Case Report.

Journal: The American journal of case reports

Published: November 14, 2025

Screening of Anti-Tumor Drugs that Enhance Antigen Presentation of AML Cells with TCR-Like Antibody

Journal: Zhongguo shi yan xue ye xue za zhi

Published: November 14, 2025

Filters

Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.

Bispecific antibody combination regimens for B-cell non-Hodgkin's lymphomas.

Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review.

Effective front-line treatment of osteosclerotic myeloma with POEMS syndrome with daratumumab, lenalidomide and dexamethasone: a case report and literature review.

Vitamin D status and chemotherapy-induced peripheral neuropathy: A scoping review.

Vitamin D status and chemotherapy-induced peripheral neuropathy: A scoping review.

Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?

Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?

Updates in low/intermediate-risk MDS.

Updates in low/intermediate-risk MDS.

Choosing the optimal maintenance strategy in multiple myeloma.

Choosing the optimal maintenance strategy in multiple myeloma.

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Endless possibilities and how to exploit them? What is the optimal treatment sequence?

Collapsing Glomerulopathy in a Patient With Myelodysplastic Syndrome With Isolated del(5q): A Case Report.

Collapsing Glomerulopathy in a Patient With Myelodysplastic Syndrome With Isolated del(5q): A Case Report.

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan.

Correlation between duration of first-line treatment with daratumumab, lenalidomide, and dexamethasone and overall survival in patients with transplant-ineligible multiple myeloma in Japan.

NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.

NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.

Daratumumab-Based Regimen Significantly Induced Remission of Crystalline Light Chain Proximal Tubulopathy: A Case Report.

Daratumumab-Based Regimen Significantly Induced Remission of Crystalline Light Chain Proximal Tubulopathy: A Case Report.

Screening of Anti-Tumor Drugs that Enhance Antigen Presentation of AML Cells with TCR-Like Antibody

Screening of Anti-Tumor Drugs that Enhance Antigen Presentation of AML Cells with TCR-Like Antibody